Despite bipartisan agreement that the high cost of drugs must be addressed, proposals to reform the U.S. drug pricing system have languished for years. There’s no shortage of ideas on what to do—Medicare price negotiation, greater price transparency, international reference pricing, patent exclusivity changes, and price controls all have their advocates. But there’s no consensus on how to strike the right balance between making drugs affordable now, and preserving financial incentives for developing new drugs in the future. Join our expert panel as they discuss the policy options for drug pricing, the appropriate roles of government and markets, and prospects for reform in the current political environment.